trending Market Intelligence /marketintelligence/en/news-insights/trending/cqTvAH0WmCaM9gC07Z9pxg2 content esgSubNav
In This List

Savara stopping development of Aironite after study fails

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Savara stopping development of Aironite after study fails

Savara Inc.'s Aironite, a sodium nitrite inhalation solution, failed to improve peak exercise capacity in certain patients with heart failure.

The study, called Indie, also failed to meet secondary goals, which included quality of life and lung efficiency at maximal exercise.

The trial was evaluating the use of inhaled inorganic nitrite for symptom relief in patients with heart failure with preserved ejection fraction, or HFpEF.

HFpEF is a form of congestive heart failure where the amount of blood pumped from the heart's left ventricle with each beat, an ejection fraction, is greater than 50%.

Savara added Aironite to its pipeline as part of the acquisition of Mast Therapeutics in April 2017. The Indie study was one of two investigator-sponsored Aironite studies in HFpEF patients initiated before the merger.

The company does not plan to support any new development of Aironite.

Texas-based Savara is a clinical-stage specialty pharmaceutical company, which focuses on developing and commercializing therapies to treat serious or life-threatening rare respiratory diseases.